USP13 and posterior cortical atrophy: The USP13 gene expression and clinicopathological characteristics of the patients were shown in S Fig. 4A and B. The methylation level of the USP13 gene promoter was found to be significantly higher in PCa tumors, tumors without TP53 mutation and tumors with or without lymph node metastasis than in normal tissue samples (S Fig. 5A – 5C); moreover, the expression of USP13 was positively associated with methyltransferases in PCa (S Fig. 5D).